

Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form

For assistance, please call 1-800-988-4861. Fax completed form to 570-271-5610.

Medical documentation may be requested. This form will be returned if not completed in full.

Member Information						
Member Name:			Prescriber Name:			
	Drocoribor's Spo	ciolty /				
	Prescriber's Spe	ciaity.				
	NDI#-					
State:	City:	State:				
Zip:	Office Phone #:	Office Fax #:	Zip:			
	O a sta at Dama and					
	Contact Person:					
nacic and Mad	lical Information					
		Fraguanavi				
		Frequency.				
	of Therapy:	Qtv:				
Apooloa Longin	or morapy.	α.γ.				
Date Therapy Initiated:						
			Date:			
ia for Initial Pr	ior Authorization					
		N BELOW IS COM	PLETE			
men (include d	dose, schedule a	nd duration):				
Please indicate the member's Hepatitis C genotype:						
iver staging (b	acad on METAV	P liver scoring):				
iver staying (b	aseu un me l'Avi	r iver sconny).				
If the member has cirrhosis, has a hepatocellular carcinoma screening been completed?						
□ Yes □No						
• Does the member have severe extrahepatic manifestations of hepatitis C (such as but not						
limited to a syndrome involving cryoglobulinemia, an immune complex disorder, and a						
		lymphoproliferative disorder that produces arthralgias, fatigue, palpable purpura, renal				
		palpable purpura	, renal			
at produces art	thralgias, fatigue,	palpable purpura as well as sympto				
	Zip: nosis and Mec trength and Rou dministration: xpected Length :: ia for Initial Pr ED UNLESS A men (include of lepatitis C ger ver staging (b s a hepatocell extrahepatic r	Prescriber Name Prescriber's Spect NPI#: Address: State: City: Zip: Office Phone #: Contact Person: Contact Person: Contact Person: Contact Person: Contact Person: Diagnosis: Diagnosis: Diagnosis: Contact Person: Diagnosis: Diagnosis: Contact Person: Contact Person: Con	Prescriber's Specialty: NPI#: Address: State: City: Zip: Office Phone #: Office Fax #: Contact Person: Contact Person: nosis and Medical Information Frequency: trength and Route of Frequency: dministration: Qty: xpected Length of Therapy: Qty: :: Diagnosis: ia for Initial Prior Authorization ED UNLESS ALL INFORMATION BELOW IS COMP men (include dose, schedule and duration): Hepatitis C genotype: ver staging (based on METAVIR liver scoring): s a hepatocellular carcinoma screening been cor extrahepatic manifestations of hepatitis C (such			

						C F	Geisinger Health Plan
	transplant? Yes	□No If yes	s, pleas	e des	cribe		
•	Have all drug interactions caused by the requested Hepatitis C regimen been addressed by the provider? What actions have been taken?						
•	• Does member have signs and symptoms of decompensated liver disease? Yes No						
•	Is the member co-inf	ected with HIV/	AIDS?			□ Yes	□No
•	 Does member have hepatocellular carcinoma (that meets Milan criteria) and is awaiting liver transplant?						
•	 Has the member been previously treated for chronic Hepatitis C? If yes, please list previous treatment, dates, duration of therapy, and treatment response (partial responder, nonresponder, or relapser): 						
R	egimen	Dates		Dura	tion of The	rapy	Treatment Response
 Have the following lab values been obtained within the last 3 months? (Please attach results) Hepatic Function Panel Yes Date Date No Complete Blood Count with differential Date Date No Basic Metabolic Panel Yes Date No Baseline HCV RNA Viral Load Yes Date No No No Baseline HCV RNA Viral Load Yes Date No No No Baseline HCV RNA Viral Load Yes Date No No							
•	What is the member	's glomerular filt	tration r	ate?	ml	L/min/1	.73m ²
•	 If using ribavirin and member is female of childbearing potential: please provide pregnancy test results and date: Positive Negative N/A 						
•	 If using ribavirin and member is male with a female partner who is of childbearing potential: are they pregnant or planning a pregnancy? Yes No N/A 						
•	 If using ribavirin: has the member been instructed to practice effective contraception during therapy and for 6 months following discontinuation of ribavirin treatment? Yes No NA 						
•	 Psychiatric Evaluation: Does member have a history of the following if requesting interferon? Prior suicide attempt						

				Geisinger Health Plan		
		ders rsonality Disorder sonality Disorder	Yes 🗆 No □ Yes □ Yes	□No □No		
	performed w Date] Nes Psychiatrist			
	Was the mer	nber cleared to start hepati	tis C treatment by the	psychiatrist? ☐ Yes ☐ No		
	If the member does not have a history of any psychiatric disorder or substance dependency disorder listed above, was a mental health evaluation performed by the prescriber? \square Yes \square No					
•	Has the member completed at least 6 months of complete abstinence from alcohol and illegal controlled substances prior to initiation of treatment? (does not apply to GHP Family members) \square Yes \square No					
•	 Is the member currently being treated for substance dependency? (does not apply to GHP Family members) □ Yes □No If yes, is the member compliant with treatment? □ Yes □No 					
•	Has a blood alcohol level screen been completed prior to initiation of treatment? (does not apply to GHP Family members) \Box Yes \Box No					
	lf yes, pl	ease list all results below:				
		Date	Result (Negative or	Positive)		
	-					
	-					
	L					
•	 Has a urine drug screen been completed prior to initiation of treatment? (does not apply to GHP Family members)					
	lf ves n	lease list all results below:				
	n yoo, p	Date	Result (Negative or	· Positive)		
	_					
	-					
	-					
•		is actively abusing alcohol n of the prescriber counseli		history of abuse, is there of alcohol or IV drug abuse,		



	and an offer of a reonly) Yes		ce use disorder treatment? (For GHP Family members			
•	Does the urine drug screen (UDS) correctly correspond with medication fill history? (does not apply to GHP Family members) \Box Yes \Box No					
•	Did the member receive pre-treatment readiness education about hepatitis C treatment expectations by a health care provider? \Box Yes \Box No					
•	 Has the member committed to the documented planned course of treatment including anticipated blood tests and visits, during and after treatment? Yes					
•	 Is the member agreeable to counseling and monitoring by representatives from Geisinger Health Plan?					
•	 Does the member have a limited life expectancy of less than 12 months due to non-liver- related co-morbid conditions?					
• Please complete and return the following information for members being treated with hepatitis C therapy with a duration longer than 12 weeks, requiring reauthorization:						
Т	reatment Week	Date of HCV	HCV RNA Viral Load Results			
		RNA Viral				
		Load Testing				
_	Baseline					
_	Veek 4 Veek 8					
	Veek 0 Veek 12					
	Veek 24					
			·			

Instructions for Completing the Form

- 1. Submit a separate form for each medication.
- 2. Complete **ALL** information on the form. NOTE: The prescribing physician should, in most cases, complete the form.
- 3. Please be sure to provide the physician address in a legible format, as it is required for notification.
- 4. Once form is completed, mail or fax to:

Geisinger Health Plan Attn: Pharmacy Department 32-45 100 N. Academy Avenue Danville, PA 17822 Fax: 570-271-5610